-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
-
Summary
-
Aerovate Therapeutics, Inc. quarterly/annual General and Administrative Expense history and growth rate from 2020 to 2023.
- Aerovate Therapeutics, Inc. General and Administrative Expense for the quarter ending June 30, 2024 was $4.92M, a 14.3% increase year-over-year.
- Aerovate Therapeutics, Inc. General and Administrative Expense for the twelve months ending June 30, 2024 was $18.2M, a 17.7% increase year-over-year.
- Aerovate Therapeutics, Inc. annual General and Administrative Expense for 2023 was $17.2M, a 17.6% increase from 2022.
- Aerovate Therapeutics, Inc. annual General and Administrative Expense for 2022 was $14.6M, a 81.9% increase from 2021.
- Aerovate Therapeutics, Inc. annual General and Administrative Expense for 2021 was $8.04M, a 747% increase from 2020.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Annual (USD)
General and Administrative Expense, YoY Annual Growth (%)